Salvage Chemotherapy in Recurrent Cervical Cancer With Biweekly Pegylated Liposomal Doxorubicin (Lipo-Dox)

Salvage Chemotherapy in Recurrent Cervical Cancer With Biweekly Pegylated Liposomal Doxorubicin (Lipo-Dox)

Objective: To investigate the objective response rate to and tolerance of biweekly Lipo-Dox (TTY Biopharm Co. Ltd., Taipei, Taiwan) at a dosage of 20 mg/m2 in previously treated patients with recurrent cervical cancer. Materials and Methods: This study was performed as a Simon's two-stage phase...

Full description

Bibliographic Details
Main Authors: Jen-Ruei Chen, Yuh-Cheng Yang, Tze-Chien Chen, Jerry Cheng-Yen Lai, Shing-Jyh Chang, Chi-Long Chang, Kung-Liahng Wang
Format: Article
Language:English
Published: Elsevier 2008-09-01
Series:Taiwanese Journal of Obstetrics & Gynecology
Subjects:
cervical cancer
chemotherapy
Lipo-Dox
recurrent
liposomal doxorubicin
Online Access:http://www.sciencedirect.com/science/article/pii/S1028455908601321

Internet

http://www.sciencedirect.com/science/article/pii/S1028455908601321

Similar Items